Kisspeptin Phase II

What It Is

Kisspeptin is the endogenous ligand of the KISS1R (previously GPR54) receptor — a Gq-coupled G-protein-coupled receptor expressed on GnRH neurons in the hypothalamic preoptic area. It was identified in 1996 as the product of the KISS1 gene on chromosome 1q32 (originally named because it was discovered in Hershey, Pennsylvania — home of Hershey's Kisses), and for several years was characterized primarily as a metastasis-suppressor (its originally-assigned function, from which the alternative name "metastin" derives). In 2003, two independent research teams — Seminara and colleagues at Massachusetts General Hospital (NEJM) and de Roux and colleagues in Paris (PNAS) — reported that loss-of-function mutations in KISS1R produced hypogonadotropic hypogonadism in humans: the clinical phenotype of absent puberty with low LH, FSH, and sex steroids despite structurally intact hypothalamus and pituitary. This finding established kisspeptin as the master upstream regulator of the HPG axis.

Kisspeptin's mature peptide hormone exists in several biologically active forms derived from proteolytic processing of the 145-amino-acid KISS1 gene product. The longest form is kisspeptin-54 (Kp-54, sometimes called "metastin"); shorter forms include kisspeptin-14, kisspeptin-13, and kisspeptin-10 (Kp-10). All share the same C-terminal decapeptide (residues 109–118 of the KISS1 precursor, "YNWNSFGLRF-NH₂") which is the pharmacophore responsible for receptor binding. Kp-10 and Kp-54 are the two forms most extensively used in human pharmacology research.

The kisspeptin system sits at the apex of reproductive neuroendocrinology. Two populations of kisspeptin-expressing neurons in the hypothalamus — the arcuate-nucleus "KNDy" neurons (co-expressing kisspeptin, neurokinin B, and dynorphin) and the anteroventral periventricular nucleus / rostral preoptic area neurons — project onto GnRH neurons. Arcuate KNDy neurons generate the pulsatile GnRH "pulse generator" responsible for the pulsatile LH/FSH secretion underlying normal reproductive function; anteroventral periventricular kisspeptin neurons mediate the estradiol-positive-feedback LH surge that triggers ovulation in females.

Clinically, kisspeptin is an active investigational agent in reproductive endocrinology. The most advanced development program is at Imperial College London under Dhillo, Jayasena, and colleagues, where kisspeptin-54 has been evaluated as an IVF ovulation trigger (replacing hCG or GnRH agonist triggers), as a diagnostic agent for hypothalamic amenorrhea, and as a candidate therapy for male and female hypogonadism. Parallel programs at Massachusetts General Hospital (Seminara lab) have characterized pediatric puberty disorders and hypothalamic amenorrhea.

Mechanism of Action

Kisspeptin's mechanism is narrowly focused at the KISS1R receptor and has been well-characterized at molecular, neuroanatomic, and clinical levels.

• KISS1R (GPR54) activation on GnRH neurons — Kisspeptin binds KISS1R, a Gq-coupled GPCR expressed densely on hypothalamic GnRH neurons. Receptor activation triggers phospholipase C, IP3, intracellular calcium mobilization, and GnRH neuron depolarization → GnRH release into the hypothalamo-pituitary portal system.
• Downstream GnRH → LH/FSH → gonadal hormones — GnRH released into the pituitary portal circulation stimulates pulsatile LH and FSH secretion from pituitary gonadotropes. In males, LH drives Leydig-cell testosterone synthesis and FSH supports Sertoli-cell spermatogenesis. In females, FSH drives follicular maturation and LH triggers ovulation and corpus luteum function.
• Pulse generator (arcuate KNDy neurons) — The kisspeptin / neurokinin B / dynorphin (KNDy) neurons of the arcuate nucleus generate the synchronized oscillatory firing that drives pulsatile GnRH release. Neurokinin B acts autocrine/paracrine to drive the ON phase; dynorphin provides the OFF phase via κ-opioid-receptor signaling. This neural circuit is the "GnRH pulse generator" whose existence had been postulated for decades before the kisspeptin/KNDy system identified it.
• Estradiol positive-feedback surge (AVPV neurons) — The anteroventral periventricular (AVPV) / rostral preoptic area kisspeptin neurons are activated by estradiol positive feedback and mediate the mid-cycle LH surge that triggers ovulation in females.
• Metabolic integration — Kisspeptin neurons receive inputs from leptin, insulin, and ghrelin — linking energy status to reproductive competence. This is why severe caloric restriction (functional hypothalamic amenorrhea, anorexia nervosa-related amenorrhea, relative-energy-deficiency-in-sport) shuts down the HPG axis: falling leptin silences kisspeptin, suppressing GnRH.
• Tachyphylaxis with continuous infusion — Continuous kisspeptin exposure desensitizes the HPG axis (mechanism analogous to continuous GnRH producing pituitary desensitization). Pulsatile dosing maintains the physiological pulse pattern and avoids desensitization — a critical pharmacologic consideration for any clinical protocol.
• Upstream of exogenous testosterone — Unlike exogenous testosterone (which suppresses endogenous LH/FSH via hypothalamic-pituitary negative feedback), kisspeptin acts upstream — stimulating the native HPG cascade. This preserves testicular volume, spermatogenesis, and fertility, in contrast to TRT's characteristic testicular atrophy and infertility.
• Reproductive-behavior modulation (limbic effects) — Kp-54 administration in humans increases limbic brain activity on fMRI in response to sexual stimuli. Attraction and sexual function effects reported with kisspeptin likely reflect both direct neural effects and downstream testosterone-mediated action.
• Non-reproductive roles — KISS1 was originally identified as a metastasis suppressor. Kisspeptin signaling is also implicated in placental biology, bone remodeling, cardiovascular function, and glucose homeostasis, though these non-reproductive functions are less characterized clinically.

What the Research Shows

Kisspeptin's published evidence is concentrated in reproductive endocrinology and largely associated with two research groups (Seminara at MGH and Dhillo/Jayasena at Imperial College London) but is methodologically strong — genetic evidence from human loss-of-function, multiple Phase 1 and Phase 2 human trials, and mechanistically coherent Phase 2 efficacy data.

• Human KISS1R loss-of-function → hypogonadotropic hypogonadism (Seminara et al., NEJM 2003; PMID 14573733 and de Roux et al., PNAS 2003) — Two independent studies identified KISS1R inactivating mutations as cause of normosmic idiopathic hypogonadotropic hypogonadism (nIHH) with absent or incomplete puberty. The foundational "reverse pharmacology" evidence establishing kisspeptin as master regulator of puberty and reproduction.
• First human administration (Dhillo et al., JCEM 2005; PMID 15886226) — IV infusion of Kp-54 in healthy men increased plasma LH, FSH, and testosterone. First human demonstration of kisspeptin-induced gonadotropin release.
• Hypothalamic amenorrhea (Jayasena et al., JCEM 2009; PMID 19454583) — Subcutaneous Kp-54 administration increased LH and restored LH pulsatility in women with hypothalamic amenorrhea. Supports clinical potential in functional HA.
• Tachyphylaxis characterization (Jayasena et al., 2009–2011) — Repeated subcutaneous Kp-54 produced rapid tachyphylaxis in women with HA, while pulsatile IV delivery maintained LH responsiveness. Established dose-frequency pharmacology guiding subsequent trials.
• Kisspeptin IVF trigger — first proof-of-concept (Jayasena et al., JCI 2014; PMID 25036713) — 53 women undergoing IVF received Kp-54 as the oocyte-maturation trigger. Kp-54 triggered mature oocyte retrieval with reduced risk of ovarian hyperstimulation syndrome (OHSS) vs hCG trigger. Established proof-of-concept for kisspeptin as IVF trigger.
• Kisspeptin IVF trigger — expanded cohort (Abbara et al., JCI 2015; PMID 26413811) — Larger cohort (60 women) at risk of OHSS. Kp-54 triggered oocyte maturation effectively with no cases of severe OHSS — important safety differentiation from hCG-triggered cycles.
• Kisspeptin trigger + hCG rescue (Abbara et al., Hum Reprod 2017) — Combined Kp-54 trigger with hCG luteal support; optimization of kisspeptin-triggered IVF protocol.
• Limbic and sexual brain activity (Comninos, Dhillo et al., J Clin Invest 2017; PMID 28112678) — Kp-54 administration in healthy men enhanced limbic-system brain activity in response to sexual and couple-bonding stimuli on fMRI. Supports the role of kisspeptin signaling in sexual attraction circuits beyond the HPG axis alone.
• Hypoactive sexual desire in women (Thurston, Comninos et al., JAMA Netw Open 2022) — Kp-54 enhanced sexual and attraction brain processing and behavioral responses in premenopausal women with hypoactive sexual desire disorder. Extends the sexual-function research to female clinical populations.
• Puberty onset (Chan et al., JCEM 2011) — Kisspeptin-10 infusion elicits a greater LH response in boys with delayed puberty than in healthy controls, consistent with upregulated KISS1R sensitivity and supporting diagnostic utility.
• Male hypogonadism pilot (Dhillo group, multiple publications 2015–2024) — Short-term kisspeptin administration increases LH and testosterone in men with functional hypogonadism, supporting potential for HPG axis "restart" protocols.

Human Data

Kisspeptin has accumulated a sizeable human database primarily from Imperial College London and Massachusetts General Hospital programs:

• Healthy-volunteer PK/PD — Multiple Phase 1 studies in healthy men and women characterizing LH, FSH, testosterone, and estradiol responses to IV and SC kisspeptin (Kp-10 and Kp-54) across dose ranges.
• Pediatric delayed puberty — Diagnostic and investigational studies in adolescents with delayed puberty.
• Functional hypothalamic amenorrhea (HA) — Multiple Jayasena/Dhillo-group trials establishing restoration of LH pulsatility.
• Male hypogonadism (functional / hypogonadotropic) — Short-course restoration of LH and testosterone in men with functional hypogonadism.
• IVF ovulation trigger — The strongest clinical endpoint to date. Jayasena JCI 2014 and Abbara JCI 2015 demonstrate safe, effective oocyte maturation with markedly reduced OHSS risk. Ongoing Phase 2/3 development in IVF.
• Kp-54 + hCG luteal-phase support — Protocol optimization for kisspeptin-triggered IVF.
• Female hypoactive sexual desire — Kp-54 enhances sexual and attraction brain processing in women with HSDD (JAMA Netw Open 2022).
• Male sexual function / attraction (fMRI) — Kp-54 enhances limbic responses to sexual/couple-bonding stimuli (Comninos et al., JCI 2017).
• No chronic dosing data — The published record is almost entirely short-course (single-dose to several-day). Long-term (months-to-years) safety and efficacy data are not available.
• No FDA pivotal trial — As of April 2026, no kisspeptin Phase 3 program is publicly listed at ClinicalTrials.gov with US FDA registration.

Dosing from the Literature

Kisspeptin dosing in the research literature is dominated by IV protocols; subcutaneous dosing in clinical research is less common but has been described. Community use (off-label, in peptide-clinic or self-dosing contexts) extrapolates from IV data and is not validated.

Reconstitution & Storage

Kisspeptin (Kp-10 or Kp-54) is supplied as a lyophilized powder, typically in 1 mg, 2 mg, or 5 mg research vials.

• Reconstitution — Add BAC water slowly down the vial wall at 45°; swirl gently, do not shake. Kisspeptin peptide is relatively hydrophilic and dissolves quickly to a clear colorless solution.
• Storage — Lyophilized: long-term storage at −20°C; short-term 2–8°C. Reconstituted: 2–8°C, use within 14–28 days. Avoid freeze-thaw cycling of reconstituted solution.
• Administration — Clinical research has used IV infusion for PK/PD work and SC bolus for IVF trigger and HA protocols. Community self-dosing is typically SC with 29–31G insulin syringe at abdomen or thigh; rotate sites.
• Pulsatile dosing — Tachyphylaxis considerations argue against continuous high-dose or constant-interval dosing for chronic applications. Short-course pulsatile (Q60–Q90 min IV in clinical protocols) preserves receptor responsiveness.
• Inspection — Discard if cloudy, discolored, or particulate. Kisspeptin is generally stable in solution but any visible change is a discard signal.

→ Use the Kalios Dosing Calculator for kisspeptin volume conversions

Side Effects & Risks

Kisspeptin has been administered to hundreds of human research volunteers and reproductive-endocrinology patients in published protocols. The safety record is favorable in this short-course research context; long-term safety is uncharacterized.

• Generally well-tolerated in published research — No serious adverse events reported in the published Phase 1 / Phase 2 studies to date. Most reported AEs are mild and self-limited.
• Injection site reactions — Mild redness or discomfort with SC administration.
• Hormonal fluctuation effects — Acute rise in LH and testosterone can produce subjective effects — libido changes, mild emotional variability in the hours post-dose. Typically reported as neutral or positive.
• Tachyphylaxis — The most important pharmacological consideration. Continuous or overly-frequent dosing desensitizes the HPG axis, blunting response. Clinical protocols use pulsatile dosing to avoid this.
• OHSS in IVF context — Importantly, Kp-54 trigger appears to substantially reduce OHSS risk vs hCG trigger. This is a reduction, not a zero-risk; patients are still monitored.
• Luteal-phase insufficiency in IVF — Kisspeptin's shorter LH-pulse profile compared to hCG means luteal-phase support is typically required after Kp-54-triggered cycles.
• Pregnancy / fetal exposure — Endogenous kisspeptin / placental kisspeptin has physiological roles in pregnancy. Exogenous kisspeptin is not approved in pregnancy; kisspeptin-triggered IVF cycles are specifically designed to produce mature oocytes prior to fertilization, with subsequent luteal support.
• Long-term safety — Uncharacterized. Chronic pulsatile HPG stimulation has theoretical implications for prostate, breast, and gonadal tissues that have not been studied in humans.
• Drug interactions — GnRH agonists and antagonists directly antagonize the downstream effect; opioids suppress the HPG axis at the hypothalamus (including the kisspeptin/dynorphin system); exogenous testosterone suppresses endogenous axis via negative feedback.
• Contraindications — Active hormone-sensitive cancer (breast, prostate), pregnancy (outside fertility-treatment context), and patients with significant cardiovascular disease should not use kisspeptin without specialist oversight.
• Purity and sourcing — Research-chemical supply varies substantially; require HPLC/MS Certificates of Analysis showing >98% purity.
• Anti-doping — Kisspeptin is not specifically named on the WADA Prohibited List but athletes should consult their federation; indirect enhancement of endogenous testosterone could plausibly fall under general HPG-manipulation categories.

Bloodwork & Monitoring

• Total and free testosterone (men) / estradiol (women) — Primary pharmacodynamic endpoints. Baseline and serial measurements during any protocol.
• LH and FSH — Direct readouts of pituitary response to kisspeptin-driven GnRH release.
• SHBG — Affects free-testosterone calculation and should be tracked alongside total.
• Prolactin — Baseline screening; not expected to change with kisspeptin, but elevated prolactin can independently suppress the HPG axis.
• Sperm analysis (male fertility context) — Baseline and post-protocol semen analysis for fertility-focused applications.
• Antral follicle count + AMH (female fertility context) — Baseline ovarian reserve assessment for IVF applications.
• CMP / CBC — Standard baseline safety labs.
• Hematocrit (men) — Rising testosterone from HPG stimulation can elevate hematocrit; monitor especially in patients with baseline polycythemia risk.
• PSA (men >40) — Age-appropriate prostate monitoring for any protocol that elevates endogenous testosterone.
• Imaging / clinical evaluation — As indicated by underlying condition (pituitary MRI for idiopathic HH evaluation, pelvic ultrasound for female fertility).

Commonly Stacked With

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

The HPG-axis toolbox — upstream, downstream, and parallel to where kisspeptin acts.

Next Steps

Key References

1. Seminara SB, Messager S, Chatzidaki EE, Thresher RR, Acierno JS Jr, Shagoury JK, et al. The GPR54 gene as a regulator of puberty. N Engl J Med. 2003;349(17):1614-1627. PMID: 14573733. (Foundational paper establishing kisspeptin-receptor loss-of-function as cause of hypogonadotropic hypogonadism.)
2. de Roux N, Genin E, Carel JC, Matsuda F, Chaussain JL, Milgrom E. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci USA. 2003;100(19):10972-10976. PMID: 12944565.
3. Dhillo WS, Chaudhri OB, Patterson M, Thompson EL, Murphy KG, Badman MK, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab. 2005;90(12):6609-6615. PMID: 16174713.
4. Jayasena CN, Nijher GM, Chaudhri OB, Murphy KG, Ranger A, Lim A, et al. Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis. J Clin Endocrinol Metab. 2009;94(11):4315-4323. PMID: 19820030.
5. Jayasena CN, Abbara A, Comninos AN, Nijher GM, Christopoulos G, Narayanaswamy S, et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. J Clin Invest. 2014;124(8):3667-3677. PMID: 25036713.
6. Abbara A, Jayasena CN, Christopoulos G, Narayanaswamy S, Izzi-Engbeaya C, Nijher GM, et al. Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy. J Clin Endocrinol Metab. 2015;100(9):3322-3331. PMID: 26192876.
7. Comninos AN, Wall MB, Demetriou L, Shah AJ, Clarke SA, Narayanaswamy S, et al. Kisspeptin modulates sexual and emotional brain processing in humans. J Clin Invest. 2017;127(2):709-719. PMID: 28112678.
8. Thurston L, Hunjan T, Ertl N, Wall MB, Mills EG, Suladze S, et al. Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2022;5(10):e2236131. PMID: 36227594.
9. Chan YM, Butler JP, Pinnell NE, Pralong FP, Crowley WF Jr, Ren C, et al. Kisspeptin resets the hypothalamic GnRH clock in men. J Clin Endocrinol Metab. 2011;96(6):E908-915. PMID: 21470993.
10. Abbara A, Eng PC, Phylactou M, Clarke SA, Hunjan T, Roberts R, et al. Kisspeptin receptor agonist has therapeutic potential for female reproductive disorders. J Clin Invest. 2020;130(12):6739-6753. PMID: 33196464.
11. Skorupskaite K, George JT, Anderson RA. The kisspeptin-GnRH pathway in human reproductive health and disease. Hum Reprod Update. 2014;20(4):485-500. PMID: 24615662.
12. Pinilla L, Aguilar E, Dieguez C, Millar RP, Tena-Sempere M. Kisspeptins and reproduction: physiological roles and regulatory mechanisms. Physiol Rev. 2012;92(3):1235-1316. PMID: 22811428.
13. Kotani M, Detheux M, Vandenbogaerde A, Communi D, Vanderwinden JM, Le Poul E, et al. The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. J Biol Chem. 2001;276(37):34631-34636. PMID: 11457843. (Identification of kisspeptin as GPR54 ligand.)
14. Clarke H, Dhillo WS, Jayasena CN. Comprehensive Review on Kisspeptin and Its Role in Reproductive Disorders. Endocrinol Metab (Seoul). 2015;30(2):124-141. PMID: 26194072.
15. Trevisan CM, Montagna E, de Oliveira R, Christofolini DM, Barbosa CP, Crandall KA, Bianco B. Kisspeptin/GPR54 System: What Do We Know About Its Role in Human Reproduction? Cell Physiol Biochem. 2018;49(4):1259-1276. PMID: 30205368.
16. Lapatto R, Pallais JC, Zhang D, Chan YM, Mahan A, Cerrato F, et al. Kiss1−/− mice exhibit more variable hypogonadism than Gpr54−/− mice. Endocrinology. 2007;148(10):4927-4936. PMID: 17595229.
17. Messager S, Chatzidaki EE, Ma D, Hendrick AG, Zahn D, Dixon J, et al. Kisspeptin directly stimulates gonadotropin-releasing hormone release via G protein-coupled receptor 54. Proc Natl Acad Sci USA. 2005;102(5):1761-1766. PMID: 15665093.